Your browser doesn't support javascript.
loading
A case report of prostate cancer with leptomeningeal metastasis and bone marrow involvement.
Garousi, Maryam; Mousavi Darzikolaee, Nima; Faridfar, Ali; Javadi, Seyed Mohammadreza; Samizadeh, Esmaeil; Sajadi Rad, Masoumeh; Bayani, Reyhaneh.
Afiliación
  • Garousi M; Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Mousavi Darzikolaee N; Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Faridfar A; Department of Radiation Oncology, Imam Khomeini Hospital Complex, School of medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Javadi SM; Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran.
  • Samizadeh E; General Surgery Department, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Sajadi Rad M; Department of pathology, School of medicine AND Imam Reza Hospital, AJA University of Medical Sciences, Tehran, Iran.
  • Bayani R; Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Cancer Rep (Hoboken) ; 7(4): e2041, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38577848
ABSTRACT

BACKGROUND:

Prostate cancer is the second most common cancer in men. Central nervous system (CNS) involvement in prostate cancer which manifests as cerebral, leptomeningeal, or dural involvement is uncommon and occurs late in the course of disease. CASE A 60-year-old patient with castration resistant prostate cancer (CRPC) presented with headache and fatigue. Evaluation revealed bone marrow and leptomeningeal involvement. The patient treated by whole brain radiotherapy, leuprolide, weekly docetaxel and daily 1000 mg abiraterone. Complete blood count (CBC) and CNS symptoms improved and the patient is alive after 11 months with excellent performance status.

CONCLUSION:

Leptomeningeal involvement in prostate cancer is rare and is associated with a poor prognosis but the possibility of such event should be considered in patients with new onset progressive CNS symptoms. New treatment strategies such as combination of docetaxel and abiraterone added to androgen deprivation therapy (triplet therapy) might improve outcome in these patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos Límite: Humans / Male / Middle aged Idioma: En Revista: Cancer Rep (Hoboken) Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos Límite: Humans / Male / Middle aged Idioma: En Revista: Cancer Rep (Hoboken) Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos